The KCNH8 antibody targets the KCNH8 protein, a member of the potassium voltage-gated channel subfamily H (KCNH). KCNH8. also known as ether-à-go-go-like potassium channel 8. is encoded by the KCNH8 gene and belongs to the EAG family of voltage-gated K⁺ channels. Structurally, it contains six transmembrane domains and a cyclic nucleotide-binding homology domain, forming tetrameric channels that regulate potassium ion flow across cell membranes. KCNH8 is predominantly expressed in the central nervous system (CNS), where it contributes to neuronal excitability, action potential repolarization, and synaptic signaling. Dysregulation of KCNH8 has been implicated in neurological disorders, including epilepsy and psychiatric conditions. Antibodies against KCNH8 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are typically developed using recombinant protein fragments or synthetic peptides as immunogens, validated for specificity via techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). Challenges in KCNH8 antibody development include cross-reactivity with homologous KCNH family members and low endogenous protein abundance in certain tissues. Reliable KCNH8 antibodies enable research into its role in CNS disorders and potential therapeutic targeting of potassium channel dysfunction.